The Venture Codex Logo

The Venture Codex

Norcliffe Capital

7 Bell Yard, London, WC2A 2JR, United Kingdom

Overview

Tax-efficient investments in life sciences and disruptive technology.

Founded

2015

Deals ยท 12mo

0

Links

WebsiteLinkedInX (Twitter)

Stage focus

Seed
Series A

Geographic focus

United Kingdom
United States

Sector focus

Financial Services

Investment portfolio

6rounds
NAMEDATESIZE
Laverock Therapeutics
Jun 2025Participated
$27 MSeed
Dxcover
Feb 2025Led
$6 MOther Equity
Oxford Endovascular
May 2024Participated
$10 MSeries A
Glen Clova Scientific
Apr 2024Led
$5 MSeed
Dxcover
Feb 2023Led
$12 MSeries A
Dxcover
Mar 2021Participated
$2 MOther Equity
Laverock Therapeutics
Jun 2025Participated
$27 MSeed
Dxcover
Feb 2025Led
$6 MOther Equity
Oxford Endovascular
May 2024Participated
$10 MSeries A
Glen Clova Scientific
Apr 2024Led
$5 MSeed
Dxcover
Feb 2023Led
$12 MSeries A
Dxcover
Mar 2021Participated
$2 MOther Equity
6
Items
Browse all public portfolio deals

Insights

Time horizon

View by

Deal Distribution

Norcliffe Capital: 6 funding rounds are recorded in the selected participation categories.All available history.
Norcliffe Capital: 6 funding rounds are recorded in the selected participation categories. All available history
Round typeLed dealsParticipated deals
Seed11
Series A11
Other Equity11

Monthly Deal Activity

Norcliffe Capital: 6 deals are recorded across 68 months.All available history.
Norcliffe Capital: 6 deals are recorded across 68 months. All available history
MonthDeals
Mar '211
Apr '210
May '210
Jun '210
Jul '210
Aug '210
Sep '210
Oct '210
Nov '210
Dec '210
Jan '220
Feb '220
Mar '220
Apr '220
May '220
Jun '220
Jul '220
Aug '220
Sep '220
Oct '220
Nov '220
Dec '220
Jan '230
Feb '231
Mar '230
Apr '230
May '230
Jun '230
Jul '230
Aug '230
Sep '230
Oct '230
Nov '230
Dec '230
Jan '240
Feb '240
Mar '240
Apr '241
May '241
Jun '240
Jul '240
Aug '240
Sep '240
Oct '240
Nov '240
Dec '240
Jan '250
Feb '251
Mar '250
Apr '250
May '250
Jun '251
Jul '250
Aug '250
Sep '250
Oct '250
Nov '250
Dec '250
Jan '260
Feb '260
Mar '260
Apr '260
May '260
Jun '260
Jul '260
Aug '260
Sep '260
Oct '260

Sector Breakdown

Norcliffe Capital: Health & Life Sciences is the largest displayed sector by deal count (6 deals).All available history.

A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.

Norcliffe Capital: Health & Life Sciences is the largest displayed sector by deal count (6 deals). All available history
SectorDeals
Health & Life Sciences6
AI & Machine Learning3

Deal Size Distribution

Norcliffe Capital: 6 rounds have a disclosed size in the displayed size bands.All available history.

Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.

Norcliffe Capital: 6 rounds have a disclosed size in the displayed size bands. All available history
Round size band (USD)Deals
<$5M2
$5M-$10M1
$10M-$25M2
$25M-$50M1
$50M-$100M0
$100M-$250M0
$250M-$500M0
$500M-$1B0
$1B+0

Deals By Geography

Norcliffe Capital: Europe has the largest recorded deal count among the displayed regions (6 deals).All available history.

Top 1 of 1 regions; European countries are grouped as Europe.

Norcliffe Capital: Europe has the largest recorded deal count among the displayed regions (6 deals). All available history
RegionDeals
Europe6
Norcliffe Capital: 18 co-investors are shown, with Eos Advisory sharing 4 recorded deals.All available history.

Co-Investors

Bubble size = shared deals

Click a bubble to open that fund in a new tab.

Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.

Norcliffe Capital: 18 co-investors are shown, with Eos Advisory sharing 4 recorded deals. All available history
Co-investorShared deals
Eos Advisory4
University of Strathclyde3
Maven Capital Partners2
Scottish Enterprise2
SIS Ventures2
Calculus Capital1
DSW Ventures1
Eli Lilly and Company1
European Innovation Council1
Investment Fund for Scotland1
Macmillan Cancer Support1
Mercia Asset Management1
Mercia Ventures1
Oxford Science Enterprises1
Parkwalk Advisors1
TRICAPITAL1
University of Oxford1
Vulpes1

Investment Strategy

Norcliffe Capital: Led accounts for 50% and participating for 50% of round participation.All available history.
Norcliffe Capital: Led accounts for 50% and participating for 50% of round participation. All available history
CategoryDeals (count)Share (%)
Led350%
Participating350%
Norcliffe Capital: Single-lead accounts for 33% and co-led for 67% of lead dynamics.All available history.
Norcliffe Capital: Single-lead accounts for 33% and co-led for 67% of lead dynamics. All available history
CategoryDeals (count)Share (%)
Single-lead133%
Co-led267%

Team

No team members found for this fund.